26 results found.

Leukemia Clinical Trial using sargramostim; busulfan; cyclophosphamide; dexamethasone; etoposide; bone marrow transplantation; hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 70 years.
- Autologous Peripheral Blood Stem Cell Transplant for Acute Non-Lymphocytic Leukemia (ANLL).
sargramostim; busulfan; cyclophosphamide; dexamethasone; etoposide; bone marrow transplantation; hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Acute Myeloid Leukemia (AML), or Acute Lymphocytic Leukemia (ALL) Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Relapsed and/or Treatment-Refractory Leukemia.
CB-839

Non-Hodgkin Lymphoma, Multiple Myleoma, Chronic Lympocytic Leukem Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 79 years.
- A Multi-Center International Hospital-Based Case-Control Study of Lymphoma in Asia (AsiaLymph).

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies.
yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemi Clinical Trial using cytology specimen collection procedure

Children's Oncology Group - Recruiting N/A to 30 years.
- A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors.
cytology specimen collection procedure

Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymph Clinical Trial using Haploidentical Bone Marrow/Kidney

Massachusetts General Hospital - Recruiting 18 years to 70 years.
- Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders.
Haploidentical Bone Marrow/Kidney

Acute Lymphocytic Leukemia Clinical Trial using Inotuzumab Ozogamicin

Pfizer - Recruiting 18 years or older.
- An Open-Label, Phase 1/2 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory CD22-Positive Acute Lymphocytic Leukemia.
Inotuzumab Ozogamicin

Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chr Clinical Trial using Fludarabine monophosphate; Busulfan; Stem Cell Infusion; Tacrolimus; Methotrexate; G-CSF

M.D. Anderson Cancer Center - Recruiting 5 years to 75 years.
- Randomized Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation.
Fludarabine monophosphate; Busulfan; Stem Cell Infusion; Tacrolimus; Methotrexate; G-CSF

Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission, Clinical Trial using POL6326; Leukapheresis; PBSC Transplant

Polyphor Ltd. - Recruiting 18 years to 75 years.
- A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies.
POL6326; Leukapheresis; PBSC Transplant

Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chroni Clinical Trial using BMS-936564 (Anti-CXCR4)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies.
BMS-936564 (Anti-CXCR4)

Acute Lymphocytic Leukemia, or Adult Lymphoblastic Lymphoma Clinical Trial using DNR; VCR; PEG-asp; CTX; Prednisone; Liposomal AraC; MTX; LCV; AraC; Etoposide; Dasatinib; Rituximab; Hydrocortisone

University of California, San Diego - Recruiting 18 years to 60 years.
- A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocytr) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
DNR; VCR; PEG-asp; CTX; Prednisone; Liposomal AraC; MTX; LCV; AraC; Etoposide; Dasatinib; Rituximab; Hydrocortisone

Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasi Clinical Trial using Chemotherapy and antibodies; Miltenyi Biotec CliniMACS; Allogeneic stem cell transplantation

St. Jude Children's Research Hospital - Recruiting N/A to 24 Months.
- HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies.
Chemotherapy and antibodies; Miltenyi Biotec CliniMACS; Allogeneic stem cell transplantation

Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, or Myelod Clinical Trial using Lupron; 18F FLT; Cyclophosphamide; Methotrexate; Tacrolimus; Total Body Irradiation

National Institutes of Health Clinical Center (CC) - Recruiting 8 years to 60 years.
- Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults With Molecular Imaging Evaluation.
Lupron; 18F FLT; Cyclophosphamide; Methotrexate; Tacrolimus; Total Body Irradiation

Acute Myeloid Leukemia, or Chronic Lymphocytic Leukemia Clinical Trial using SG2000

Spirogen - Recruiting 18 years to 60 years.
- An Open-Label, Phase 1/Phase 2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of the DNA Minor Groove Binding Agent SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia.
SG2000

Acute Lymphocytic Leukaemia Clinical Trial using SAR3419

Sanofi - Recruiting 16 years or older.
- Phase II Two Stage Finding Run-in Study of SAR3419, An Anti-CD19 Antibody-Maytansine Conjugate, Administered as a Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.
SAR3419

Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic M Clinical Trial using iTreg

Masonic Cancer Center, University of Minnesota - Recruiting 18 years to 75 years.
- Dose Escalation Study With Extension of Inducible Regulatory T Cells (iTregs) in Adult Patients Undergoing Non-Myeloablative HLA Identical Sibling Donor Peripheral Blood Stem Cell Transplantation.
iTreg

Acute Lymphocytic Leukemia Clinical Trial using Biological/Genetically Modified T cells

Memorial Sloan-Kettering Cancer Center - Recruiting N/A to 19 years.
- A Phase I Dose Escalation Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the B-Cell Specific Antigen CD19 Positive Residual Or Relapsed Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation.
Biological/Genetically Modified T cells

B Cell Lymphoma, or Chronic Lymphocytic Leukemia Clinical Trial using CD19CAR-28-zeta T cells; Ipilimumab

Baylor College of Medicine - Recruiting N/A or older.
- Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, Acute Lymphocytic Leukemia, and Chronic Lymphocytic Leukemia.
CD19CAR-28-zeta T cells; Ipilimumab

Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic My Clinical Trial using HSC835

Novartis - Recruiting 10 years to 55 years.
- A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies.
HSC835

Acute Lymphocytic Leukemia, or Acute Myeloid Leukemia Clinical Trial

St. Jude Children's Research Hospital - Recruiting 5 years or older.
- Transfusional Iron Overload Among Leukemia Survivors.

Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodys Clinical Trial using Donor Lymphocyte Infusion; Induction Chemotherapy + DLI

Masonic Cancer Center, University of Minnesota - Recruiting 1 year to 70 years.
- Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant.
Donor Lymphocyte Infusion; Induction Chemotherapy + DLI

Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MD Clinical Trial using Stem Cell Transplant; Cyclophosphamide; Total Body Irradiation; Busulfan

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 55 years.
- Allogeneic Transplant for Hematological Malignancy.
Stem Cell Transplant; Cyclophosphamide; Total Body Irradiation; Busulfan

Acute Myeloid Leukemia, or Acute Lymphocytic Leukemia Clinical Trial using DFP-10917

Delta-Fly Pharma, Inc. - Recruiting 18 years or older.
- A Phase I/II Study of DFP 10917 Given by Continuous Infusion in Patients With Relapsed or Refractory Acute Leukemia.
DFP-10917

Adult Acute Lymphocytic Leukemia Clinical Trial using Cyclophosphamide; Dexamethasone; Vincristine; daunorubicin; Asparaginase; Methotrexate; Cytarabine; Mercaptopurine; G-CSF; Vindesine; VP16; Prednisolone; Adriamycin; Thioguanine; VM26; CNS irradiation; Mediastinal Irradiation; Stem cell transplantation; Idarubicin; Fludarabine; Cladribine

Johann Wolfgang Goethe University Hospitals - Recruiting 15 years to 65 years.
- German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003).
Cyclophosphamide; Dexamethasone; Vincristine; daunorubicin; Asparaginase; Methotrexate; Cytarabine; Mercaptopurine; G-CSF; Vindesine; VP16; Prednisolone; Adriamycin; Thioguanine; VM26; CNS irradiation; Mediastinal Irradiation; Stem cell transplantation; Idarubicin; Fludarabine; Cladribine

Multiple Myeloma, Lymphoma, Acute Myelogenous Leukemia, Acute Lym Clinical Trial using Tacrolimus and MMF

Colorado Blood Cancer Institute - Recruiting 50 years to 70 years.
- Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched Family Donor Hematopoietic Cell Transplants.
Tacrolimus and MMF